Systematic computer-aided disulfide design as a general strategy to stabilize prefusion class I fusion proteins.
Disulfides
/ chemistry
Animals
Viral Fusion Proteins
/ immunology
Humans
Respiratory Syncytial Virus Infections
/ immunology
Protein Stability
Computer-Aided Design
Protein Conformation
Respiratory Syncytial Viruses
/ immunology
Respiratory Syncytial Virus Vaccines
/ immunology
Rats
Models, Molecular
class I fusion proteins
computational modeling
disulfide design
prefusion stabilization
vaccine development
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
25
03
2024
accepted:
03
07
2024
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
8
8
2024
Statut:
epublish
Résumé
Numerous enveloped viruses, such as coronaviruses, influenza, and respiratory syncytial virus (RSV), utilize class I fusion proteins for cell entry. During this process, the proteins transition from a prefusion to a postfusion state, undergoing substantial and irreversible conformational changes. The prefusion conformation has repeatedly shown significant potential in vaccine development. However, the instability of this state poses challenges for its practical application in vaccines. While non-native disulfides have been effective in maintaining the prefusion structure, identifying stabilizing disulfide bonds remains an intricate task. Here, we present a general computational approach to systematically identify prefusion-stabilizing disulfides. Our method assesses the geometric constraints of disulfide bonds and introduces a ranking system to estimate their potential in stabilizing the prefusion conformation. We hypothesized that disulfides restricting the initial stages of the conformational switch could offer higher stability to the prefusion state than those preventing unfolding at a later stage. The implementation of our algorithm on the RSV F protein led to the discovery of prefusion-stabilizing disulfides that supported our hypothesis. Furthermore, the evaluation of our top design as a vaccine candidate in a cotton rat model demonstrated robust protection against RSV infection, highlighting the potential of our approach for vaccine development.
Identifiants
pubmed: 39114655
doi: 10.3389/fimmu.2024.1406929
pmc: PMC11303214
doi:
Substances chimiques
Disulfides
0
Viral Fusion Proteins
0
Respiratory Syncytial Virus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1406929Informations de copyright
Copyright © 2024 Gonzalez, Yim, Blanco, Boukhvalova and Strauch.
Déclaration de conflit d'intérêts
Authors KY, JB, and MB were employed by the company Sigmovir Biosystems, Inc. KG and E-MS are inventors of an ongoing US patent application No.18/404,463. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.